

# Global Gene Therapy for Age-related Macular Degeneration Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

<https://marketpublishers.com/r/G85B9BA5B4EEN.html>

Date: December 2018

Pages: 118

Price: US\$ 3,480.00 (Single User License)

ID: G85B9BA5B4EEN

## Abstracts

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

### Scope of the Report:

This report studies the Gene Therapy for Age-related Macular Degeneration market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy for Age-related Macular Degeneration market by product type and applications/end industries.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, The global age-related macular degeneration market

will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

The global Gene Therapy for Age-related Macular Degeneration market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy for Age-related Macular Degeneration.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

RetroSense Therapeutics

REGENXBIO

AGTC

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Subretinal

Intravitreal

Unspecified

Market Segment by Applications, can be divided into

Monotherapy

Combination Therapy

## Contents

### **1 GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION MARKET OVERVIEW**

- 1.1 Product Overview and Scope of Gene Therapy for Age-related Macular Degeneration
- 1.2 Classification of Gene Therapy for Age-related Macular Degeneration by Types
  - 1.2.1 Global Gene Therapy for Age-related Macular Degeneration Revenue Comparison by Types (2017-2023)
  - 1.2.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Types in 2017
  - 1.2.3 Subretinal
  - 1.2.4 Intravitreal
  - 1.2.5 Unspecified
- 1.3 Global Gene Therapy for Age-related Macular Degeneration Market by Application
  - 1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Size and Market Share Comparison by Applications (2013-2023)
  - 1.3.2 Monotherapy
  - 1.3.3 Combination Therapy
- 1.4 Global Gene Therapy for Age-related Macular Degeneration Market by Regions
  - 1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size (Million USD) Comparison by Regions (2013-2023)
    - 1.4.1 North America (USA, Canada and Mexico) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
    - 1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
    - 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
    - 1.4.4 South America (Brazil, Argentina, Colombia) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
    - 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
- 1.5 Global Market Size of Gene Therapy for Age-related Macular Degeneration (2013-2023)

### **2 MANUFACTURERS PROFILES**

#### 2.1 RetroSense Therapeutics

- 2.1.1 Business Overview
- 2.1.2 Gene Therapy for Age-related Macular Degeneration Type and Applications
  - 2.1.2.1 Product A
  - 2.1.2.2 Product B
- 2.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)
- 2.2 REGENXBIO
  - 2.2.1 Business Overview
  - 2.2.2 Gene Therapy for Age-related Macular Degeneration Type and Applications
    - 2.2.2.1 Product A
    - 2.2.2.2 Product B
  - 2.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)
- 2.3 AGTC
  - 2.3.1 Business Overview
  - 2.3.2 Gene Therapy for Age-related Macular Degeneration Type and Applications
    - 2.3.2.1 Product A
    - 2.3.2.2 Product B
  - 2.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)

### **3 GLOBAL GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION MARKET COMPETITION, BY PLAYERS**

- 3.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Share by Players (2013-2018)
- 3.2 Market Concentration Rate
  - 3.2.1 Top 5 Gene Therapy for Age-related Macular Degeneration Players Market Share
  - 3.2.2 Top 10 Gene Therapy for Age-related Macular Degeneration Players Market Share
- 3.3 Market Competition Trend

### **4 GLOBAL GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION MARKET SIZE BY REGIONS**

- 4.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Market Share by Regions
- 4.2 North America Gene Therapy for Age-related Macular Degeneration Revenue and

Growth Rate (2013-2018)

4.3 Europe Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

4.5 South America Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

## **5 NORTH AMERICA GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION REVENUE BY COUNTRIES**

5.1 North America Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)

5.2 USA Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

5.3 Canada Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

5.4 Mexico Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

## **6 EUROPE GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION REVENUE BY COUNTRIES**

6.1 Europe Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)

6.2 Germany Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

6.3 UK Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

6.4 France Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

6.5 Russia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

6.6 Italy Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

## **7 ASIA-PACIFIC GENE THERAPY FOR AGE-RELATED MACULAR**

## **DEGENERATION REVENUE BY COUNTRIES**

- 7.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
- 7.2 China Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 7.3 Japan Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 7.4 Korea Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 7.5 India Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 7.6 Southeast Asia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

## **8 SOUTH AMERICA GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION REVENUE BY COUNTRIES**

- 8.1 South America Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
- 8.2 Brazil Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 8.3 Argentina Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 8.4 Colombia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

## **9 MIDDLE EAST AND AFRICA REVENUE GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION BY COUNTRIES**

- 9.1 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
- 9.2 Saudi Arabia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 9.3 UAE Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 9.4 Egypt Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
- 9.5 Nigeria Gene Therapy for Age-related Macular Degeneration Revenue and Growth

Rate (2013-2018)

9.6 South Africa Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

## **10 GLOBAL GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION MARKET SEGMENT BY TYPE**

10.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Market Share by Type (2013-2018)

10.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Type (2018-2023)

10.3 Subretinal Revenue Growth Rate (2013-2023)

10.4 Intravitreal Revenue Growth Rate (2013-2023)

10.5 Unspecified Revenue Growth Rate (2013-2023)

## **11 GLOBAL GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION MARKET SEGMENT BY APPLICATION**

11.1 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2013-2018)

11.2 Gene Therapy for Age-related Macular Degeneration Market Forecast by Application (2018-2023)

11.3 Monotherapy Revenue Growth (2013-2018)

11.4 Combination Therapy Revenue Growth (2013-2018)

## **12 GLOBAL GENE THERAPY FOR AGE-RELATED MACULAR DEGENERATION MARKET SIZE FORECAST (2018-2023)**

12.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2018-2023)

12.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Regions (2018-2023)

12.3 North America Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

12.4 Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

12.6 South America Gene Therapy for Age-related Macular Degeneration Revenue

Market Forecast (2018-2023)

12.7 Middle East and Africa Gene Therapy for Age-related Macular Degeneration

Revenue Market Forecast (2018-2023)

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Data Source

## List Of Tables

### LIST OF TABLES AND FIGURES

Figure Gene Therapy for Age-related Macular Degeneration Picture

Table Product Specifications of Gene Therapy for Age-related Macular Degeneration

Table Global Gene Therapy for Age-related Macular Degeneration and Revenue (Million USD) Market Split by Product Type

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Types in 2017

Figure Subretinal Picture

Figure Intravitreal Picture

Figure Unspecified Picture

Table Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Application (2013-2023)

Figure Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Applications in 2017

Figure Monotherapy Picture

Figure Combination Therapy Picture

Table Global Market Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) Comparison by Regions 2013-2023

Figure North America Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (2013-2023)

Figure Europe Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (2013-2023)

Figure Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (2013-2023)

Figure South America Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (2013-2023)

Figure Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (2013-2023)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (2013-2023)

Table RetroSense Therapeutics Basic Information, Manufacturing Base and Competitors

Table RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Type and Applications

Table RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)

Table REGENXBIO Basic Information, Manufacturing Base and Competitors

Table REGENXBIO Gene Therapy for Age-related Macular Degeneration Type and Applications

Table REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)

Table AGTC Basic Information, Manufacturing Base and Competitors

Table AGTC Gene Therapy for Age-related Macular Degeneration Type and Applications

Table AGTC Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Players (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Players (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Players in 2016

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Players in 2017

Figure Global Top 5 Players Gene Therapy for Age-related Macular Degeneration Revenue Market Share in 2017

Figure Global Top 10 Players Gene Therapy for Age-related Macular Degeneration Revenue Market Share in 2017

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate (%) (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Regions (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Regions (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Regions (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Regions in 2017

Figure North America Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Europe Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure South America Gene Therapy for Age-related Macular Degeneration Revenue

and Growth Rate (2013-2018)

Figure Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Table North America Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)

Table North America Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure North America Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure North America Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries in 2017

Figure USA Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Canada Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Mexico Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Table Europe Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Countries (2013-2018)

Figure Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries in 2017

Figure Germany Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure UK Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure France Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Russia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Italy Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Table Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Countries (2013-2018)

Figure Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries in 2017

Figure China Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Japan Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Korea Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure India Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Southeast Asia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Table South America Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)

Table South America Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure South America Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure South America Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries in 2017

Figure Brazil Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Argentina Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Colombia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Table Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Countries (2013-2018)

Table Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Countries in 2017

Figure Saudi Arabia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure UAE Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Egypt Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Figure Nigeria Gene Therapy for Age-related Macular Degeneration Revenue and

Growth Rate (2013-2018)

Figure South Africa Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) by Type (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Type (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Type (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Type in 2017

Table Global Gene Therapy for Age-related Macular Degeneration Revenue Forecast by Type (2018-2023)

Figure Global Gene Therapy for Age-related Macular Degeneration Market Share Forecast by Type (2018-2023)

Figure Global Subretinal Revenue Growth Rate (2013-2018)

Figure Global Intravitreal Revenue Growth Rate (2013-2018)

Figure Global Unspecified Revenue Growth Rate (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue by Application (2013-2018)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Application (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Application (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Share by Application in 2017

Table Global Gene Therapy for Age-related Macular Degeneration Revenue Forecast by Application (2018-2023)

Figure Global Gene Therapy for Age-related Macular Degeneration Market Share Forecast by Application (2018-2023)

Figure Global Monotherapy Revenue Growth Rate (2013-2018)

Figure Global Combination Therapy Revenue Growth Rate (2013-2018)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) and Growth Rate Forecast (2018 -2023)

Table Global Gene Therapy for Age-related Macular Degeneration Revenue (Million USD) Forecast by Regions (2018-2023)

Figure Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share Forecast by Regions (2018-2023)

Figure North America Gene Therapy for Age-related Macular Degeneration Revenue

Market Forecast (2018-2023)

Figure Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

Figure Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

Figure South America Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

Figure Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)

## I would like to order

Product name: Global Gene Therapy for Age-related Macular Degeneration Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Product link: <https://marketpublishers.com/r/G85B9BA5B4EEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G85B9BA5B4EEN.html>